GE Studies Demonstrate Use of MultiOmyx Platform for Lymphoma Diagnosis, Breast Cancer Research | GenomeWeb

GE Healthcare this week released results from a pair of studies researching use of its MultiOmyx protein detection system in lymphoma and breast cancer.

The studies comprised an assessment of the company's nine-protein Hodgkin Lymphoma Profile assay, which it launched in July through its Clarient Diagnostic Services division, and an exploratory research effort using the system to evaluate known prognostic biomarkers in breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.